Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous daratumumab with talquetamab or teclistamab for relapsed/refractory multiple myeloma
NL-OMON54604Phase 1Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of daratumumab, talquetamab, teclistamab and pomalidomide in multiple myeloma (MM) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Frequency and severity of dose-limiting toxicities and Frequency and severity of adverse events and serious adverse events. Started Jun 2021; status: recruiting.
02
Drugs
daratumumabtalquetamabteclistamabpomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON54604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54604.